Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 0.87 |
| ▸ | THRA | P10827 | 19/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.87 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.87 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.87 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.87 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22632499 | 1.00 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL13907340 | 0.93 | THRB (1.00) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632387 | 0.93 | THRB (0.78) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29414827 | 0.91 | THRB (0.91) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632456 | 0.91 | THRB (0.91) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL31643583 | 0.88 | THRB (0.89) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632753 | 0.87 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22643856 | 0.87 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22643857 | 0.87 | THRB (0.87) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23022537 | 0.86 | THRA (0.88) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |